186 related articles for article (PubMed ID: 34597380)
1. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
Mitchell AP; Mishra Meza A; Panageas KS; Lipitz-Snyderman A; Bach PB; Morris MJ
J Natl Cancer Inst; 2022 Mar; 114(3):419-426. PubMed ID: 34597380
[TBL] [Abstract][Full Text] [Related]
2. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Mitchell AP; Meza AM; Panageas KS; Lipitz-Snyderman A; Farooki A; Morris MJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):126-132. PubMed ID: 35798857
[TBL] [Abstract][Full Text] [Related]
3. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
[TBL] [Abstract][Full Text] [Related]
4. Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate.
Fukuokaya W; Mori K; Urabe F; Igarashi T; Yanagisawa T; Tsuzuki S; Honda M; Miki K; Kimura T
JAMA Netw Open; 2024 Mar; 7(3):e242467. PubMed ID: 38488793
[TBL] [Abstract][Full Text] [Related]
5. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
[TBL] [Abstract][Full Text] [Related]
6. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
Stoffel ST; von Moos R; Thürlimann B; Cathomas R; Gillessen S; Zürrer-Härdi U; von Briel T; Anchisi S; Feller A; Schär C; Dietrich D; Schwenkglenks M; Lupatsch JE; Mark MT
Swiss Med Wkly; 2021 Mar; 151():w20464. PubMed ID: 33705559
[TBL] [Abstract][Full Text] [Related]
7. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
[TBL] [Abstract][Full Text] [Related]
9. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.
Swami U; Hong A; El-Chaar NN; Ramaswamy K; Diessner BJ; Blauer-Peterson CJ; Sandin R; Nimke D; Agarwal N
J Urol; 2023 Jun; 209(6):1120-1131. PubMed ID: 36789668
[TBL] [Abstract][Full Text] [Related]
10. Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis.
Miyashita H; Satoi S; Cruz C; Kim SM; Patel VG
Support Care Cancer; 2022 Jan; 30(1):855-863. PubMed ID: 34392414
[TBL] [Abstract][Full Text] [Related]
11. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.
Alzahrani M; Clemons M; Sienkiewicz M; Shrem NS; McGee SF; Vandermeer L; Sehdev S; Savard MF; Awan A; Canil C; Hutton B; Pond G; Saunders D; Ng T
Support Care Cancer; 2021 Nov; 29(11):6903-6912. PubMed ID: 34023950
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
[TBL] [Abstract][Full Text] [Related]
13. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
Oncologist; 2023 Sep; 28(9):780-789. PubMed ID: 37014080
[TBL] [Abstract][Full Text] [Related]
15. Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.
AlZahrani M; Clemons M; Vandermeer L; Sienkiewicz M; Awan AA; Hutton B; Pond GR; Ng TL
J Bone Oncol; 2021 Feb; 26():100339. PubMed ID: 33294318
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States.
Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George D
J Med Econ; 2024; 27(1):381-391. PubMed ID: 38420699
[TBL] [Abstract][Full Text] [Related]
17. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
Ryan CJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Freedland SJ
J Urol; 2021 Dec; 206(6):1420-1429. PubMed ID: 34293915
[TBL] [Abstract][Full Text] [Related]
18. Vertical integration of oncologists and cancer outcomes and costs in metastatic castration-resistant prostate cancer.
Hu X; Lipscomb J; Jiang C; Graetz I
J Natl Cancer Inst; 2023 Mar; 115(3):268-278. PubMed ID: 36583540
[TBL] [Abstract][Full Text] [Related]
19. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer. Evolution of osteoprotective strategies].
Todenhöfer T; Schwentner C; Schilling D; Gakis G; Stenzl A
Urologe A; 2011 Sep; 50(9):1055-63. PubMed ID: 21744161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
